Lsv Asset Management increased its stake in The Goodyear Tire & Rubber Company (GT) by 3.93% based on its latest 2018Q1 regulatory filing with the SEC. Lsv Asset Management bought 420,600 shares as the company’s stock declined 15.53% with the market. The institutional investor held 11.11 million shares of the automotive aftermarket company at the end of 2018Q1, valued at $295.33 million, up from 10.69 million at the end of the previous reported quarter. Lsv Asset Management who had been investing in The Goodyear Tire & Rubber Company for a number of months, seems to be bullish on the $6.01B market cap company. The stock decreased 0.12% or $0.03 during the last trading session, reaching $25.07. About 2.58M shares traded. The Goodyear Tire & Rubber Company (NASDAQ:GT) has declined 21.33% since June 17, 2017 and is downtrending. It has underperformed by 33.90% the S&P500. Some Historical GT News: 17/04/2018 – MOODY’S PLACES DEALER TIRE RATINGS UNDER REVIEW FOR DOWNGRADE; 09/04/2018 – GOODYEAR TIRE & RUBBER CO – ANNOUNCED RE-ELECTION OF 12 MEMBERS OF BOARD OF DIRECTORS TO NEW ONE-YEAR TERMS; 16/04/2018 – GOODYEAR TIRE & RUBBER CO – CO EXPECTS TO RECORD MAJORITY OF SHARE OF START-UP COSTS IN OTHER INCOME & EXPENSE DURING FIRST & SECOND QUARTERS OF 2018; 16/04/2018 – Goodyear Tire, Bridgestone Americas, to Form Tire Distribution Joint Venture in U.S; 16/04/2018 – GOODYEAR TIRE & RUBBER CO – NO CASH WILL BE EXCHANGED BETWEEN PARTIES AS PART OF DEAL; 25/04/2018 – Goodyear Tire 1Q Americas Tire Unit Volume Fell 3%; 25/04/2018 – Goodyear Tire 1Q EPS 31c; 25/04/2018 – Goodyear Tire Confirms 2020 Segment Operating Income Target of $2B-$2.4B; 15/05/2018 – MOODY’S CONFIRMS DEALER TIRE RATINGS; OUTLOOK STABLE; 25/04/2018 – GOODYEAR 1Q ADJ EPS 50C, EST. 46C
Ecor1 Capital Llc increased its stake in Immune Design Corp (IMDZ) by 24.56% based on its latest 2018Q1 regulatory filing with the SEC. Ecor1 Capital Llc bought 875,000 shares as the company’s stock rose 30.77% while stock markets declined. The institutional investor held 4.44M shares of the major pharmaceuticals company at the end of 2018Q1, valued at $14.42M, up from 3.56M at the end of the previous reported quarter. Ecor1 Capital Llc who had been investing in Immune Design Corp for a number of months, seems to be bullish on the $223.78M market cap company. The stock increased 3.33% or $0.15 during the last trading session, reaching $4.65. About 302,294 shares traded or 12.98% up from the average. Immune Design Corp. (NASDAQ:IMDZ) has declined 47.53% since June 17, 2017 and is downtrending. It has underperformed by 60.10% the S&P500. Some Historical IMDZ News: 02/05/2018 – IMMUNE DESIGN STILL ON TRACK TO ENROLL CMB305 PATIENTS BY MIDYR; 12/03/2018 IMDZ: MEDIAN OVERALL SURVIVAL OF 23.7 MOS FOLLOWING CMB305; 23/04/2018 – DJ Immune Design Corp, Inst Holders, 1Q 2018 (IMDZ)
Investors sentiment increased to 0.99 in Q1 2018. Its up 0.24, from 0.75 in 2017Q4. It increased, as 38 investors sold GT shares while 148 reduced holdings. 50 funds opened positions while 134 raised stakes. 201.95 million shares or 4.42% less from 211.29 million shares in 2017Q4 were reported. Alliancebernstein Ltd Partnership reported 0.01% stake. Columbia Asset Management holds 9,500 shares. Blb&B Advsr Llc holds 0.27% in The Goodyear Tire & Rubber Company (NASDAQ:GT) or 77,377 shares. Qs Limited Com has invested 0% of its portfolio in The Goodyear Tire & Rubber Company (NASDAQ:GT). Metropolitan Life Ins reported 37,449 shares. 57,338 were reported by State Of Alaska Department Of Revenue. Laurion Mgmt Limited Partnership holds 98,619 shares or 0.02% of its portfolio. Convergence Investment Ptnrs Limited Liability Corp holds 0% or 633 shares in its portfolio. Hotchkis And Wiley Mngmt Ltd Liability holds 6.21M shares. Tortoise Capital Advisors Ltd Liability Co invested in 31 shares. Sei Invests owns 0.01% invested in The Goodyear Tire & Rubber Company (NASDAQ:GT) for 82,336 shares. Cibc Asset Mngmt holds 0% or 23,249 shares. Norinchukin Bank & Trust The holds 22,022 shares or 0.01% of its portfolio. Letko Brosseau And Assocs accumulated 2.81M shares or 0.7% of the stock. Salem Mgmt has invested 2.05% in The Goodyear Tire & Rubber Company (NASDAQ:GT).
Among 13 analysts covering Goodyear Tire (NASDAQ:GT), 7 have Buy rating, 0 Sell and 6 Hold. Therefore 54% are positive. Goodyear Tire had 38 analyst reports since October 28, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, July 28 by Morgan Stanley. The rating was maintained by Argus Research with “Buy” on Tuesday, November 10. As per Thursday, June 1, the company rating was upgraded by Morgan Stanley. The rating was maintained by Jefferies on Thursday, October 12 with “Buy”. On Thursday, April 26 the stock rating was maintained by JP Morgan with “Overweight”. The company was maintained on Thursday, April 19 by Guggenheim. The stock has “Buy” rating by Jefferies on Tuesday, November 29. The rating was maintained by Jefferies on Sunday, January 28 with “Buy”. Morgan Stanley maintained it with “Overweight” rating and $34 target in Thursday, March 22 report. Jefferies maintained the stock with “Buy” rating in Wednesday, April 4 report.
Another recent and important The Goodyear Tire & Rubber Company (NASDAQ:GT) news was published by Investorplace.com which published an article titled: “3 Cheapest Stocks With Greatest Potential for Growth” on May 29, 2018.
Lsv Asset Management, which manages about $82.68 billion and $62.96 billion US Long portfolio, decreased its stake in Lockheed Martin Corporation (NYSE:LMT) by 5,100 shares to 5,945 shares, valued at $2.01 million in 2018Q1, according to the filing. It also reduced its holding in Xl Capital Finance (Europe) Plc. by 68,600 shares in the quarter, leaving it with 1.39M shares, and cut its stake in Cabot Corporation (NYSE:CBT).
More recent Immune Design Corp. (NASDAQ:IMDZ) news were published by: Seekingalpha.com which released: “Is Immune Design Worth A Second Look?” on June 12, 2018. Also Streetinsider.com published the news titled: “Immune Design (IMDZ) Reports Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in …” on May 24, 2018. Nasdaq.com‘s news article titled: “Immune Design to Host June 4 Cancer Immunotherapy Event in Chicago and Present at Jefferies 2018 Global …” with publication date: June 01, 2018 was also an interesting one.
Among 5 analysts covering Immune Design (NASDAQ:IMDZ), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Immune Design had 11 analyst reports since August 18, 2015 according to SRatingsIntel. Jefferies initiated it with “Buy” rating and $30 target in Wednesday, September 9 report. Jefferies maintained it with “Buy” rating and $18.0 target in Thursday, October 5 report. As per Monday, June 26, the company rating was maintained by Jefferies. Leerink Swann initiated Immune Design Corp. (NASDAQ:IMDZ) rating on Tuesday, August 18. Leerink Swann has “Outperform” rating and $40 target. The firm earned “Buy” rating on Tuesday, June 6 by Cowen & Co. The firm has “Buy” rating given on Monday, September 4 by Jefferies. Jefferies maintained Immune Design Corp. (NASDAQ:IMDZ) on Wednesday, August 10 with “Buy” rating. The firm has “Market Perform” rating by Wells Fargo given on Wednesday, October 18. Jefferies maintained the stock with “Buy” rating in Thursday, March 15 report.
Ecor1 Capital Llc, which manages about $997.01M US Long portfolio, decreased its stake in Dicerna Pharmaceuticals Ord (NASDAQ:DRNA) by 72,100 shares to 4.76 million shares, valued at $45.55M in 2018Q1, according to the filing. It also reduced its holding in Ascendis Pharma by 285,025 shares in the quarter, leaving it with 1.82M shares, and cut its stake in Celgene Corporation (Call).
Since January 4, 2018, it had 0 buys, and 5 sales for $66,512 activity. Yurasov Sergey had sold 675 shares worth $2,816. 1,986 shares were sold by ter Meulen Jan Henrik, worth $8,282 on Thursday, January 4. Brady Stephen R had sold 3,328 shares worth $13,885. 1,986 shares were sold by Gombotz Wayne, worth $8,282.